

Actions arising from previous meeting and other updates

Presented by Maria Filancia, Industry liaison specialist



Actions arising from the 14th ISG meeting

Topic	Action	Follow up
Vulnerability assessment	 ISG to provide feedback on Vulnerability Assessment Methodology by 3rd October 2025. EMA to organise an MSSG-Industry meeting. 	completed
Update on the Shortage Mitigation Plan (SMP)/Shortage Prevention Plan (SPP)	 EMA to share the report of the pilot phase once published. 	Will be shared asap
Update on the European Platform for Regulatory Science Research	 Industry to submit 1 nomination for observer to the European Platform for Regulatory Science Research by EOB 28th October 	• completed
HMA-EMA Catalogues of real-world data sources and studies	 Industry to gather the feedback from affiliated member and nominate a speaker to present the consolidated feedback at the next meeting of the ISG in December. 	 Topic for discussion at the 15th ISG meeting
Patients Experience Data reflection paper update	 ISG members to promote industry members contribution to the PED public consultation (by 31/01/2026) and therapeutic areas survey (by 19/10/2025). EMA to evaluate a possible workshop after the feedback from the PED reflection paper public consultation. 	• ongoing
AI research needs in medicines lifecycle survey	 ISG to promote industry members contribution to the survey by EOB 17th October 2025. ISG to provide nominations for AI focus group by EOB 24th October 2025. 	• completed



Other important updates and reminders

Topic	Details	
Quarterly System Demo – Q4 2025	 Tuesday 16 December 2025, 09:30 – 12:35 (CET) 10 product demos: eAF, eCTD4, UPD, PMS, PUI, ePI, RPM/IRIS, CTIS, ASU, DAP Agenda and livestream link on the event page https://www.ema.europa.eu/en/events/quarterly-system-demo-q4-2025 	
Product Management Service (PMS) call for industry SME nominations	 4 subject matter experts (SMEs) representing large, medium, and small pharmaceutical companies (including small and medium sized enterprises) as well as innovative, generic and biologic pharmaceutical companies. Deadline for nominations 30 January 2026. 	





Thank you

emaindustryliaison@ema.europa.eu

Follow us





